ABN 16 165 160 841

ASX RELEASE **29 January 2019**

4C Quarterly Cash Flow Report

Amplia Therapeutics Limited (ASX Code: ATX) has today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2018.

The cash balance as at 31 December 2018 was $1,582,000. Net cash outflows during the quarter totalled $119,000 after receiving a Research & Development incentive payment of $218,000 in October.

The total estimated cash outflow for the quarter ending 31 March 2019 is $888,000 of which $555,000 relates to projected Research and Development expenditure. This expenditure includes a number of non-recurring costs. These are costs associated with the successful transfer and production scale up of the drug manufacturing process to an FDA approved international organisation ($325,000) and initial formal toxicology programme studies ($157,000).

These activities are directly related to positioning the Company's lead drug candidate AMP945 for an initial Phase I healthy volunteer study which is expected to provide the necessary safety, tolerability, pharmacokinetic, and pharmacodynamic data to support a Phase II programme in either cancer or fibrotic disease.

- End

For Further Information

Simon Wilkinson, CEO
+64 21 661 850
www.ampliatx.com

+Rule 4.7B

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Amplia Therapeutics Limited

ABN	**Quarter ended ("current quarter")**
16 165 160 841	31 December 2018

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers		
1.2	Payments for		
	(a) research and development	<80>	<164>
	(b) product manufacturing and operating costs		
	(c) advertising and marketing		
	(d) leased assets		
	(e) staff costs	<136>	<497>
	(f) administration and corporate costs	<112>	<327>
1.3	Dividends received (see note 3)		
1.4	Interest received	6	15
1.5	Interest and other costs of finance paid		
1.6	Income taxes paid		
1.7	Government grants and tax incentives		
1.8	Other		
	Intellectual property costs	<16>	<92>
	R&D tax refund	218	218
	Refund of trial deposits	-	225
	Miscellaneous	1	<25>
1.9	**Net cash from / (used in) operating activities**	**<119>**	**<647>**

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) property, plant and equipment	-	<3>
	(b) businesses (see item 10)		
	(c) investments		
	(d) intellectual property		
	(e) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment		
	(b) businesses (see item 10)		
	(c) investments		
	(d) intellectual property		
	(e) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	**Net cash from / (used in) investing activities**	**-**	**<3>**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of shares		
3.2	Proceeds from issue of convertible notes		
3.3	Proceeds from exercise of share options		
3.4	Transaction costs related to issues of shares, convertible notes or options	-	<12>
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	**Net cash from / (used in) financing activities**	**-**	**<12>**

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of quarter/year to date	1,694	2,229
4.2	Net cash from / (used in) operating activities (item 1.9 above)	<119>	<647>
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	<3>
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	<12>
4.5	Effect of movement in exchange rates on cash held	7	15
4.6	**Cash and cash equivalents at end of quarter**	**1,582**	**1,582**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	283	465
5.2	Call deposits	1,299	1,229
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,582**	**1,694**

6.	**Payments to directors of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to these parties included in item 1.2	49
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

This item includes payments to the CEO for remuneration totalling NZ$53,076 (i.e. A$49,553) for the quarter.

7.	Payments to related entities of the entity and their associates	Current quarter $A'000
7.1	Aggregate amount of payments to these parties included in item 1.2	
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	

7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

8.	Financing facilities available *Add notes as necessary for an understanding of the position*	Total facility amount at quarter end $A'000	Amount drawn at quarter end $A'000
8.1	Loan facilities		
8.2	Credit standby arrangements		
8.3	Other (please specify)		

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.


9.	Estimated cash outflows for next quarter	$A'000
9.1	Research and development	<555>
9.2	Product manufacturing and operating costs	-
9.3	Advertising and marketing	-
9.4	Leased assets	-
9.5	Staff costs	<148>
9.6	Administration and corporate costs	<98>
9.7	Other Intellectual property costs	<87>
9.8	**Total estimated cash outflows**	**<888>**

10.	**Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)**	**Acquisitions**	**Disposals**
10.1	Name of entity		
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Sign here:  Date: 29 January 2019

(Director/~~Company secretary~~)

Print name: Simon Wilkinson

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.